Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

Anna Morra,Maartje A C Schreurs,Irene L Andrulis,Hoda Anton-Culver,Annelie Augustinsson,Matthias W Beckmann,Sabine Behrens,Stig E Bojesen,Manjeet K Bolla,Hiltrud Brauch,Annegien Broeks,Saundra S Buys,Nicola J Camp,Jose E Castelao,Melissa H Cessna,Jenny Chang-Claude,Wendy K Chung,NBCS Collaborators,Sarah V Colonna,Fergus J Couch,Angela Cox,Simon S Cross,Kamila Czene,Mary B Daly,Joe Dennis,Peter Devilee,Thilo Dörk,Alison M Dunning,Miriam Dwek,Douglas F Easton,Diana M Eccles,Mikael Eriksson,D Gareth Evans,Peter A Fasching,Tanja N Fehm,Jonine D Figueroa,Henrik Flyger,Marike Gabrielson,Manuela Gago-Dominguez,Montserrat García-Closas,José A García-Sáenz,Jeanine Genkinger,Felix Grassmann,Melanie Gündert,Eric Hahnen,Christopher A Haiman,Ute Hamann,Patricia A Harrington,Jaana M Hartikainen,Reiner Hoppe,John L Hopper,Richard S Houlston,Anthony Howell,ABCTB Investigators,kConFab Investigators,Anna Jakubowska,Wolfgang Janni,Helena Jernström,Esther M John,Nichola Johnson,Michael E Jones,Vessela N Kristensen,Allison W Kurian,Diether Lambrechts,Loic Le Marchand,Annika Lindblom,Jan Lubiński,Michael P Lux,Arto Mannermaa,Dimitrios Mavroudis,Anna Marie Mulligan,Taru A Muranen,Heli Nevanlinna,Ines Nevelsteen,Patrick Neven,William G Newman,Nadia Obi,Kenneth Offit,Andrew F Olshan,Tjoung-Won Park-Simon,Alpa V Patel,Paolo Peterlongo,Kelly-Anne Phillips,Dijana Plaseska-Karanfilska,Eric C Polley,Nadege Presneau,Katri Pylkäs,Brigitte Rack,Paolo Radice,Muhammad U Rashid,Valerie Rhenius,Mark Robson,Atocha Romero,Emmanouil Saloustros,Elinor J Sawyer,Rita K Schmutzler,Sabine Schuetze,Christopher Scott,Mitul Shah,Snezhana Smichkoska,Melissa C Southey,William J Tapper,Lauren R Teras,Rob A E M Tollenaar,Katarzyna Tomczyk,Ian Tomlinson,Melissa A Troester,Celine M Vachon,Elke M van Veen,Qin Wang,Camilla Wendt,Hans Wildiers,Robert Winqvist,Argyrios Ziogas,Per Hall,Paul D P Pharoah,Muriel A Adank,Antoinette Hollestelle,Marjanka K Schmidt,Maartje J Hooning,Kristine K Sahlberg,Anne-Lise Børresen-Dale,Inger Torhild Gram,Karina Standahl Olsen,Olav Engebråten,Bjørn Naume,Jürgen Geisler,Grethe I Grenaker Alnaes,Christine Clarke,Deborah Marsh,Rodney Scott,Robert Baxter,Desmond Yip,Jane Carpenter,Alison Davis,Nirmala Pathmanathan,Peter Simpson,J Dinny Graham,Mythily Sachchithananthan,David Amor,Lesley Andrews,Yoland Antill,Rosemary Balleine,Jonathan Beesley,Ian Bennett,Michael Bogwitz,Leon Botes,Meagan Brennan,Melissa Brown,Michael Buckley,Jo Burke,Phyllis Butow,Liz Caldon,Ian Campbell,Michelle Cao,Anannya Chakrabarti,Deepa Chauhan,Manisha Chauhan,Georgia Chenevix-Trench,Alice Christian,Paul Cohen,Alison Colley,Ashley Crook,James Cui,Eliza Courtney,Margaret Cummings,Sarah-Jane Dawson,Anna DeFazio,Martin Delatycki,Rebecca Dickson,Joanne Dixon,Ted Edkins,Stacey Edwards,Gelareh Farshid,Andrew Fellows,Georgina Fenton,Michael Field,James Flanagan,Peter Fong,Laura Forrest,Stephen Fox,Juliet French,Michael Friedlander,Clara Gaff,Mike Gattas,Peter George,Sian Greening,Marion Harris,Stewart Hart,Nick Hayward,John Hopper,Cass Hoskins,Clare Hunt,Paul James,Mark Jenkins,Alexa Kidd,Judy Kirk,Jessica Koehler,James Kollias,Sunil Lakhani,Mitchell Lawrence,Jason Lee,Shuai Li,Geoff Lindeman,Lara Lipton,Liz Lobb,Sherene Loi,Graham Mann,Sue Anne McLachlan,Bettina Meiser,Roger Milne,Sophie Nightingale,Shona O'Connell,Sarah O'Sullivan,David Gallego Ortega,Nick Pachter,Jia-Min Pang,Gargi Pathak,Briony Patterson,Amy Pearn,Kelly Phillips,Ellen Pieper,Susan Ramus,Edwina Rickard,Bridget Robinson,Mona Saleh,Anita Skandarajah,Elizabeth Salisbury,Christobel Saunders,Jodi Saunus,Clare Scott,Adrienne Sexton,Andrew Shelling,Melissa Southey,Amanda Spurdle,Jessica Taylor,Renea Taylor,Heather Thorne,Alison Trainer,Kathy Tucker,Jane Visvader,Logan Walker,Rachael Williams,Ingrid Winship,Mary Ann Young,Milita Zaheed

DOI: https://doi.org/10.1002/cam4.6272

Abstract:Background: Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. Aim: To assessed the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. Methods: Analyses were based on 82,701 women diagnosed with a first primary invasive BC including 963 CHEK2 c.1100delC carriers; median follow-up was 9.1 years. Differential associations with treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi-state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. Results: There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status. The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR (95% CI): 0.66 (0.55-0.78)]. No association was observed with radiotherapy. Results from the multi-state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non-carriers also after accounting for CBC occurrence [HR (95% CI): 1.30 (1.09-1.56)]. Conclusion: Systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk.